| 查看: 412 | 回复: 1 | ||
| 本帖产生 1 个 翻译EPI ，点击这里进行查看 | ||
cainiaodui新虫 (小有名气)
|
[求助]
翻译求助
|
|
| Although Notch inhibitors are still preclinical, the monoclonal VEGF antibody bevacizumab is clinically available and represents a potential for combination therapy. As discussed above, some tumors are responsive to VEGF inhibition, although others are unresponsive and become resistant over time.This is most likely due to compensation by other angiogenic pathways that maintain the tumor vasculature. In patients with metastatic breast cancer, treatment with anti-VEGF therapy did not show a statistically significant increase in overall survival benefit.However, combination anti-angiogenic therapy may be useful in overcoming this resistance. |
回复此楼» 猜你喜欢
307中医考研调剂
已经有4人回复
-
通信工程求调剂！！！
已经有5人回复
-
求调剂
已经有14人回复
-
药学求调剂
已经有13人回复
-
一志愿华中农业071010，320求调剂
已经有12人回复
-
290调剂生物0860
已经有43人回复
-
一志愿沪9，生物学326求调剂
已经有7人回复
-
296求调剂
已经有12人回复
-
生物学调剂
已经有9人回复
-
0854求调剂
已经有6人回复
RXMCDM
版主 (文坛精英)
- 翻译EPI: 530
- 应助: 401 (硕士)
- 贵宾: 1.908
- 金币: 38947.6
- 散金: 4908
- 红花: 88
- 沙发: 4
- 帖子: 11453
- 在线: 1355.6小时
- 虫号: 2739168
- 注册: 2013-10-20
- 性别: GG
- 专业: 一般管理理论与研究方法论
- 管辖: 论文翻译
2楼2014-04-26 20:53:46
